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Metformin is widely used as a glucose-lowering agent in
patients with type 2 diabetes (T2D). Recently, several
studies have confirmed that metformin possessed mul-
tiple cardiovascular protective effects such as decreasing
cardiovascular mortality, attenuating adverse cardiac and
vascular remodeling and ameliorating atherosclerosis
[1–3]. Hong et al. [4] in a multicenter, randomized,
double-blind, placebo-controlled clinical trial found
treatment with metformin for 3 years substantially reduced
major cardiovascular events in a median follow-up of
5.0 years compared with glipizide in type 2 diabetes patients
who had a history of coronary artery disease. Forouzandeh
et al. [5] demonstrated metformin treatment significantly
attenuated high-fat diet-induced atherosclerosis in apo-
lipoprotein E-knockout (ApoE−/−) mice. These studies
suggest metformin could ameliorate atherosclerosis,
but the anti-atherosclerotic mechanism of metformin
remains to be fully clarified.
Previous studies reported that metformin could decrease
plasma cholesterol levels in diabetic and non-diabetic pa-
tients beyond its glucose-lowering effect [6–9], and the
lipid-lowering effect of metformin was also confirmed in a
meta-analysis of randomized controlled trials (RCTs) [10].
Besides, it was found that metformin treatment could
lower inflammation markers levels in patients at high
risk of cardiovascular disease and restore impaired
HDL-mediated cholesterol efflux from macrophages
due to glycation [11, 12]. These effects may contribute
to the anti-atherosclerotic properties of metformin.
The deposition of excessive cholesterol in macrophages
plays a key role in atherosclerotic plaque formation, thus
removal of excess cholesterol from macrophages may at-
tenuate and even regress the atherosclerosis [13]. It has
been identified that removal of cholesterol from macro-
phages was mediated by several transmembrane trans-
porters, including adenosine triphosphate binding cassette
(ABC) transporters A1 and G1 [14]. Yvan-Charvet et al.
[15] evidenced that combined deficiency of Abca1 and
Abcg1 in macrophages severely damaged cholesterol ef-
flux and accelerated atherosclerosis in low-density lipo-
protein receptor-knockout (Ldlr-/-) mice. Bochem et al.
[16] demonstrated that carriers of ABCA1 loss-of-
function mutations presented with lower cholesterol efflux
capacity and higher atherosclerotic burden compared with
age and sex-matched controls. Conversely, increased
expression of ABCA1 and ABCG1 was involved in re-
distribution of cholesterol from inner to outer leaflet of
the plasma membrane, facilitating cholesterol efflux from
cholesterol-loaded macrophages [17]. Overexpression of
ABCA1 in macrophages increased cholesterol efflux by
about 60 % (P = 0.0006) and reduced atherosclerotic
plaques by about 68 % (P = 0.0008) in Ldlr-/- mice fed a
Western-type diet for 12 weeks [18]. Thus, ABCA1- and
ABCG1-driven cholesterol efflux in macrophages was a
key regulator in anti-atherosclerosis.
Fibroblast growth factor (FGF) 21, a member of FGF
subfamily and mainly secreted by liver and adipose
tissue, is a novel metabolic regulator with multiple car-
dioprotective efficacy [19]. It was found that FGF21
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deficiency caused a marked exacerbation of atherosclerotic
plaque formation in ApoE−/− mice [20]. Moreover, previ-
ous studies also demonstrated that FGF21 could activate
ABCA1 and ABCG1 expression of macrophages and in
turn promoted cholesterol efflux in macrophages [21, 22],
suggesting up-regulation of FGF21 exerted function of
reducing atherosclerotic plaques. Intriguingly, Nygaard
et al. [23] found metformin significantly increased FGF21
expression in both rat and human hepatocytes. Another
study showed metformin could increase serum FGF21
levels both in mice and human [24]. Thus, we speculate
metformin stimulates ABCA1 and ABCG1 expression via
up-regulation of FGF21.
Taken together, we hypothesize metformin increases
FGF21 expression, and subsequently promotes expression
of ABCA1 and ABCG1 in macrophages, which promotes
cholesterol efflux from macrophages and attenuated ath-
erosclerotic plaques. Further exploring cardioprotective
mechanism of metformin will be useful for insight into
novel therapeutic targets.
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